We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Genmab A/S is one of the best cancer stocks on our list.
TheFly reported on January 8 that Deutsche Bank raised its price target for GMAB to DKK 2,400 from DKK 2,000 and reiterated a Buy rating, reflecting analysts’ optimism about the company’s late-stage oncology pipeline.
Separately, a day earlier, on January 7, Genmab A/S (NASDAQ:GMAB) partnered with AI research company Anthropic to enhance its R&D capabilities using agentic AI powered by Claude models. While keeping human control, the AI will automate complicated data processing and document creation. The partnership is a move toward a more scalable, effective, and digitally enabled R&D process, according to Tahamtan Ahmadi, EVP and Chief Medical Officer.
Genmab A/S is a biotechnology company specializing in oncology, developing innovative antibody-based therapies for cancer treatment. Its late-stage pipeline includes promising programs like Rina‑S and Epkinly.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
